---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116420"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:34:40.413385+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics Q3 2024: completes VIRAGE enrollment, cash $16.4M, impairment charges

## Summary
- Completed enrollment of 92 evaluable patients in VIRAGE Phase 2b trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma.
- Cash and cash equivalents totaled $16.4M at Sep 30, 2024, down from $23.2M at Dec 31, 2023.
- R&D expenses decreased 32% to $2.7M; G&A expenses increased to $2.3M partly due to contingent consideration adjustments.
- Recorded impairment charges of $1.3M on in-process R&D and $1.5M on goodwill due to decline in stock price.
- Discussions initiated with regulators to potentially expand VIRAGE into Phase 3 registrational trial; also positive progress in retinoblastoma program.

## SEC filing metadata
- accession: 0001104659-24-116420
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465924116420/0001104659-24-116420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465924116420/tm2426982d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116420
- JSON: https://secwatch.observer/filing/0001104659-24-116420.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116420.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.